Search Result

Results for "

α-1 adrenoceptor antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (6) Adrenergic Receptor (67) Chloride Channel (1) Dopamine Receptor (7) GHSR (1) Isotope-Labeled Compounds (5) mAChR (1) Parasite (3) STAT (5)
By Research Areas:	Cancer (9) Cardiovascular Disease (29) Endocrinology (43) Inflammation/Immunology (2) Metabolic Disease (10) Neurological Disease (14)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106612

Abanoquil U-K52046; Albanoquil	Adrenergic Receptor	Cardiovascular Disease
Abanoquil (U-K52046), an potent and selective **α-1 adrenoceptor** antagonist, is an anti-arrhythmic agent. Abanoquil can be used for erectile dysfunction research ^[1] .

HY-107326

Bunazosin	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Bunazosin is a potent and selective *α1-adrenoceptor* antagonist. Bunazosin can be used for antihypertensive and ocular hypotensive research ^[1].

HY-B0354A

Urapidil hydrochloride	5-HT Receptor Adrenergic Receptor	Cardiovascular Disease Endocrinology
Urapidil hydrochloride is an orally active *α1-adrenoceptor* antagonist and 5-HT_1A receptor agonist with a pIC₅₀ of 6.13 and 4.38 against α1- and α2-adrenoceptor, respectively. Urapidil hydrochloride shows antihypertensive effect ^[1] .

HY-135552

Benoxathian hydrochloride	Adrenergic Receptor	Endocrinology
Benoxathian hydrochloride is a potent α1 adrenoceptor antagonist, can be used for researching anorexia ^[1].

HY-B0354AR

Urapidil (hydrochloride) (Standard)	5-HT Receptor Adrenergic Receptor	Cardiovascular Disease Endocrinology
Urapidil (hydrochloride) (Standard) is the analytical standard of Urapidil (hydrochloride). This product is intended for research and analytical applications. Urapidil hydrochloride is an orally active *α1-adrenoceptor* antagonist and 5-HT_1A receptor agonist with a pIC₅₀ of 6.13 and 4.38 against α1- and α2-adrenoceptor, respectively. Urapidil hydrochloride shows antihypertensive effect ^[1] .

HY-105798

Butanserin R 53393	Adrenergic Receptor	Cardiovascular Disease
Butanserin (R 53393) is a potent and selective *α1-adrenoceptor* antagonist for the study of cardiovascular disease ^[1].

HY-107326A

Bunazosin hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Bunazosin hydrochloride is a potent and selective *α1-adrenoceptor* antagonist. Bunazosin hydrochloride can be used for antihypertensive and ocular hypotensive research ^[1].

HY-U00399

Fiduxosin	Adrenergic Receptor	Endocrinology
Fiduxosin is a potent *α1-adrenoceptor* antagonist, with K_i of 0.160 nM, 24.9 nM, and 0.920 nM for α1a-, α1b-, and α1d-adrenoceptors, respectively.

HY-131449

Terazosin dimer impurity dihydrochloride	Adrenergic Receptor	Others
Terazosin dimer impurity dihydrochloride, a dimer of Terazosin, is an impurity of Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist ^[1].

HY-U00399A

Fiduxosin hydrochloride ABT 980	Adrenergic Receptor	Endocrinology
Fiduxosin hydrochloride (ABT 980) is a potent *α1-adrenoceptor* antagonist, with K_i of 0.160 nM, 24.9 nM, and 0.920 nM for α1a-, α1b-, and α1d-adrenoceptors, respectively ^[1].

HY-B0371B

(R)-Terazosin	Adrenergic Receptor	Endocrinology
(R)-Terazosin is an active R-enantiomer of Terazosin. (R)-Terazosin is a potent *α1-adrenoceptor* antagonist with K_i values of 6.51 nM, 1.01 nM and 1.97 nM for *α1a, α1b* and *α1d-adrenoceptor*, respectively ^[1].

HY-N6969

Dicentrine	Adrenergic Receptor	Endocrinology
Dicentrine is a natural product isolated from the plant Stephania epigaea Lo with antihypertensive effect. Dicentrine is an *α₁-adrenoceptor* antagonist which has effective against human hyperplastic prostates ^[1].

HY-101061

2-MPMDQ	Adrenergic Receptor	Cardiovascular Disease
2-MPMDQ is a potent and selective *α1-adrenoceptor* (K_i=0.37 nM) antagonist over α2-adrenoceptor (K_i=1740 nM). 2-MPMDQ is potent anti-hypertensive agent and has the potential for hypertension research ^[1].

HY-U00365

5-HT2 antagonist 1	5-HT Receptor Adrenergic Receptor	Cardiovascular Disease Endocrinology
5-HT2 antagonist 1 is a potent antagonist of 5-HT2 receptor, with weak α1 adrenoceptor blocking activity.

HY-B0192A

Alfuzosin hydrochloride 1 Publications Verification SL 77499-10	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive *α1-adrenoceptor* antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) ^[1] .

HY-B0192

Alfuzosin 1 Publications Verification SL 77499	Adrenergic Receptor	Endocrinology
Alfuzosin (SL 77499-10) is an orally active, selective and competitive *α1-adrenoceptor* antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) ^[1] .

HY-B0371

Terazosin	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin is a quinazoline derivative and a competitive and orally active *α1-adrenoceptor* antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment ^[1] .

HY-B0371F

Terazosin hydrochloride Maximum Cited Publications 6 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active *α1-adrenoceptor* antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment ^[1] .

HY-136935

Alloyohimbine	Adrenergic Receptor	Endocrinology
Alloyohimbine, an alkaloid, is a selective *α2-adrenoceptor* antagonist with K_Dα1, K_Dα2 of 0.28 μM and 0.006 μM, respectively ^[1].

HY-14903

Ulimorelin TZP-101	GHSR Adrenergic Receptor	Metabolic Disease
Ulimorelin (TZP-101) is a ghrelin receptor (GRLN) agonist with an EC₅₀ of 29 nM and a K_i of 16 nM. Ulimorelin is a prokinetic agent and causes vasorelaxation through competitive antagonist action at *α1-adrenoceptors*. Ulimorelin stimulates intestinal motility and is used for malnutrition ^[1] .

HY-D1606

BODIPY FL prazosin	Adrenergic Receptor	Metabolic Disease
BODIPY FL prazosin is a fluorescent *α1-adrenergic* antagonist with K_i values of 14.5, 43.3 nM for α1a-AR and α1b-AR, respectively. BODIPY FL prazosin also is a fluorescent ligand with the excitation and emission wavelengths are 485 and 535 nm, respectively. BODIPY FL prazosin can be used for study the differences in the subcellular localization of α1-adrenoceptor subtypes ^[1] .

HY-12987

Pimozide 4 Publications Verification R6238	Dopamine Receptor Adrenergic Receptor STAT Parasite	Neurological Disease Endocrinology Cancer
Pimozide is a dopamine receptor antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at *α1-adrenoceptor, with a K_i* of 39 nM; Pimozide also inhibits STAT3 and STAT5.

HY-B0371A

Terazosin hydrochloride dihydrate Maximum Cited Publications 6 Publications Verification	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active *α1-adrenoceptor* antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment ^[1] .

HY-19037

SM-2470	Adrenergic Receptor	Cardiovascular Disease Neurological Disease Metabolic Disease
SM-2470 is a potent *α1-adrenoceptor* antagonist, has sympathetic nerve activity in anesthetized rats ^[1]. SM-2470 is an antihypertensive agent. SM-2470 exhibits hypocholesterolaemic effect by the inhibition of cholesterol absorption related to the reduction of cholesterol solubilization .

HY-101690

QF0301B	Adrenergic Receptor	Cardiovascular Disease Endocrinology
QF0301B is an α1 adrenergic receptor antagonist and a low α2 adrenoceptor, 5-HT2A, and histamine H1 receptor blocker.

HY-106874

Delequamine RS-15385-197	Adrenergic Receptor	Neurological Disease
Delequamine (RS-15385-197) is an orally active and selective α2-adrenergic receptor antagonist with a pK_i of 9.5 for α2-adrenoceptors in rat cortex. Delequamine shows >1000 fold selectivity against 5-HT1A receptors and α1-adrenoceptors. Delequamine can be used for the study of erectile dysfunction ^[1].

HY-106874A

Delequamine hydrochloride RS-15385-197 hydrochloride	Adrenergic Receptor	Neurological Disease
Delequamine (RS-15385-197) hydrochloride is an orally active and selective α2-adrenergic receptor antagonist with a pK_i of 9.5 for α2-adrenoceptors in rat cortex. Delequamine hydrochloride shows >1000 fold selectivity against 5-HT1A receptors and α1-adrenoceptors. Delequamine hydrochloride can be used for the study of erectile dysfunction ^[1].

HY-B0371S

Terazosin-d8	Isotope-Labeled Compounds Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

HY-B0192S

Alfuzosin-d7 SL 77499-d₇	Adrenergic Receptor	Endocrinology
Alfuzosin-d₇ is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].

HY-B0192AR

Alfuzosin hydrochloride (Standard)	Adrenergic Receptor	Endocrinology
Alfuzosin (hydrochloride) (Standard) is the analytical standard of Alfuzosin (hydrochloride). This product is intended for research and analytical applications. Alfuzosin (SL 77499-10) hydrochloride is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin hydrochloride relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin hydrochloride can be used in study of benign prostatic hyperplasia (BPH) ^[1] .

HY-B0371FR

Terazosin (hydrochloride) (Standard)	Adrenergic Receptor	Cardiovascular Disease Metabolic Disease Endocrinology
Terazosin (hydrochloride) (Standard) is the analytical standard of Terazosin (hydrochloride). This product is intended for research and analytical applications. Terazosin hydrochloride is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment ^[1] .

HY-12987R

Pimozide (Standard) R6238 (Standard)	Dopamine Receptor Adrenergic Receptor STAT Parasite	Neurological Disease Endocrinology Cancer
Pimozide (Standard) is the analytical standard of Pimozide. This product is intended for research and analytical applications. Pimozide is a dopamine receptor antagonist, with K_is of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at *α1-adrenoceptor, with a K_i* of 39 nM; Pimozide also inhibits STAT3 and STAT5.

HY-12987S1

Pimozide-d5 N-Oxide	Isotope-Labeled Compounds Dopamine Receptor Adrenergic Receptor STAT	Neurological Disease Endocrinology Cancer
Pimozide-d₅ N-Oxide is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2].

HY-12987S

Pimozide-d4 R6238-d₄	Dopamine Receptor Adrenergic Receptor STAT	Neurological Disease Endocrinology Cancer
Pimozide-d₄ is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3].

HY-B0192S3

Alfuzosin-d6 SL 77499-d₆	Isotope-Labeled Compounds Adrenergic Receptor	Endocrinology
Alfuzosin-d₆ (SL 77499-d₆) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive *α1-adrenoceptor* antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) ^[1] .

HY-12987S2

Pimozide-d4-1 R6238-d₄-1	Dopamine Receptor Adrenergic Receptor STAT Parasite	Neurological Disease Endocrinology Cancer
Pimozide-d₄-1 is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3][4].

HY-B0371AR

Terazosin (hydrochloride dihydrate) (Standard)	Adrenergic Receptor	Metabolic Disease Endocrinology
Terazosin (hydrochloride dihydrate) (Standard) is the analytical standard of Terazosin (hydrochloride dihydrate). This product is intended for research and analytical applications. Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment ^[1] .

HY-106954

Upidosin Rec 15/2739; Recordati 15/2739; SB 216469	Adrenergic Receptor	Inflammation/Immunology
Upidosin (Rec 15/2739) is an α-1 adrenoceptor (α-1 AR) antagonist. Upidosin shows moderate selectivity for the α-1A AR subtype. Upidosin shows uroselectivity in urethra and prostate with a K_b value of 2-3 nM higher than in ear artery and aorta with a K_b value of 20-100 nM. Upidosin inhibits [3H]prazosin binding to cloned human α-1A adrenergic receptor. Upidosin can be used for the research of urethral obstruction ^[1].

HY-101641

NRA-0160	Dopamine Receptor 5-HT Receptor Adrenergic Receptor	Neurological Disease Endocrinology
NRA-0160 is a selective dopamine D4 receptor antagonist, with a K_i value of 0.48 nM and with negligible affinity for dopamine D2 receptor (K_i: >10000 nM), D3 receptor (K_i: 39 nM), rat 5-HT2A receptor (K_i: 180 nM) and rat α1 adrenoceptor (K_i: 237 nM).

HY-106416

Neldazosin	Adrenergic Receptor	Cardiovascular Disease
Neldazosin is a potent *alpha1-adrenoceptor* antagonist ^[1].

HY-123368

Zolertine hydrochloride	Adrenergic Receptor	Cardiovascular Disease
Zolertine hydrochloride is an *α-adrenoceptor* antagonist with a pK_i of 6.81 in rat liver (α_1B-adrenoceptors) and 6.35 in rabbit liver (α_1A-adrenoceptors) membranes ^[1].

HY-B0391B

Naftopidil hydrochloride KT-611 hydrochloride; BM-15275 hydrochloride	Adrenergic Receptor	Cancer
Naftopidil hydrochloride (KT-611 hydrochloride) is a selective *alpha1-adrenoceptor* antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil hydrochloride has antiproliferative effects. Naftopidil hydrochloride can be used for the research of prostate hyperplasia ^[1].

HY-B0391

Naftopidil KT-611; BM-15275	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil (KT-611) is is a selective *alpha1-adrenoceptor* antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia ^[1] .

HY-B0391A

Naftopidil dihydrochloride KT-611 dihydrochloride; BM-15275 dihydrochloride	Adrenergic Receptor	Cancer
Naftopidil dihydrochloride (KT-611 dihydrochloride) is a selective *alpha1-adrenoceptor* antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil dihydrochloride has antiproliferative effects. Naftopidil dihydrochloride can be used for the research of prostate hyperplasia ^[1] .

HY-U00237

L-771688	Adrenergic Receptor	Endocrinology Cancer
L-771688 is a highly selective *α1A-Adrenoceptor* antagonist with a K_i of 0.43±0.02 nM.

HY-B0391S1

Naftopidil-d5 KT-611-d₅; BM-15275-d₅	Isotope-Labeled Compounds Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

HY-B0391R

Naftopidil (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Naftopidil (Standard) is the analytical standard of Naftopidil. This product is intended for research and analytical applications. Naftopidil (KT-611) is is a selective *alpha1-adrenoceptor* antagonist, with K_is of 3.7 nM, 20 nM and 1.2 nM for the cloned human α_1a-, α_1b- and α_1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia ^[1] .

HY-135270

ADRA1D receptor antagonist 1	Adrenergic Receptor	Endocrinology
ADRA1D receptor antagonist 1 is a potent, selective and orally active **α_1D adrenoceptor** antagonist, with a K_i of 1.6 nM ^[1].

HY-P1442

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective *α1A-adrenoceptor* antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia ^[1].

HY-19279A

JTH-601 free base	Others	Endocrinology
JTH-601 Free base is a novel alpha1-adrenoceptor antagonist that exhibits potent activity in inhibiting phenylephrine-induced contractions in lower urinary tract tissues. JTH-601 Free base competitively antagonizes alpha1-adrenoceptor-mediated contractile responses, demonstrating greater potency than prazosin or tamsulosin. JTH-601 Free base is anticipated to be effective in treating urinary outlet obstruction associated with benign prostatic hyperplasia.

Cat. No.	Product Name	Type

HY-D1606

BODIPY FL prazosin	Fluorescent Dyes/Probes
BODIPY FL prazosin is a fluorescent *α1-adrenergic* antagonist with K_i values of 14.5, 43.3 nM for α1a-AR and α1b-AR, respectively. BODIPY FL prazosin also is a fluorescent ligand with the excitation and emission wavelengths are 485 and 535 nm, respectively. BODIPY FL prazosin can be used for study the differences in the subcellular localization of α1-adrenoceptor subtypes ^[1] .

Cat. No.	Product Name	Target	Research Area

HY-P1442

AdTx1	Adrenergic Receptor	Cancer
AdTx1 is a selective *α1A-adrenoceptor* antagonist (K_i: 0.35 nM). AdTx1 can be used for research of benign prostatic hyperplasia ^[1].

HY-P5846

Muscarinic toxin 3 MT3	mAChR Adrenergic Receptor	Neurological Disease
Muscarinic toxin 3 (MT3) is a potent and non-competitive mAChR and *adrenoceptors* antagonist with pIC₅₀s of 6.71, 8.79, 8.86, 7.57, 8.13, 8.49, <6.5, 7.29 against M₁, M₄, α_1A, α_1B, α_1D,α_2A,α_2B and α_2C receptors, respectively. Muscarinic toxin 3 displays prominent adrenoceptor activity ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6969

Dicentrine	Alkaloids Structural Classification Classification of Application Fields Source classification Stephania epigaea Lo Plants Isoquinoline Alkaloids Menispermaceae Disease Research Fields Endocrinology	Adrenergic Receptor
Dicentrine is a natural product isolated from the plant Stephania epigaea Lo with antihypertensive effect. Dicentrine is an *α₁-adrenoceptor* antagonist which has effective against human hyperplastic prostates ^[1].

HY-B0371

Terazosin	Classification of Application Fields Disease Research Fields Endocrinology	Adrenergic Receptor
Terazosin is a quinazoline derivative and a competitive and orally active *α1-adrenoceptor* antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment ^[1] .

HY-136935

Alloyohimbine	Apocynaceae Alkaloids Structural Classification Source classification Alstonia scholaris (L.) R. Br. Plants Indole Alkaloids	Adrenergic Receptor
Alloyohimbine, an alkaloid, is a selective *α2-adrenoceptor* antagonist with K_Dα1, K_Dα2 of 0.28 μM and 0.006 μM, respectively ^[1].

Cat. No.	Product Name	Chemical Structure

HY-12987S

Pimozide-d4
Pimozide-d₄ is a deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3].

HY-12987S2

Pimozide-d4-1
Pimozide-d₄-1 is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2][3][4].

HY-B0371S

Terazosin-d8
Terazosin-d₈ is deuterium labeled Terazosin. Terazosin is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin works by relaxing blood vessels and the opening of the bladder. Terazosin has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

HY-B0192S

Alfuzosin-d7
Alfuzosin-d₇ is the deuterium labeled Alfuzosin[1]. Alfuzosin (SL 77499-10) is an orally active, selective and competitive α1-adrenoceptor antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH)[2][3].

HY-12987S1

Pimozide-d5 N-Oxide
Pimozide-d₅ N-Oxide is the deuterium labeled Pimozide. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5[1][2].

HY-B0192S3

Alfuzosin-d6
Alfuzosin-d₆ (SL 77499-d₆) is deuterium labeled Alfuzosin. Alfuzosin (SL 77499-10) is an orally active, selective and competitive *α1-adrenoceptor* antagonist. Alfuzosin relaxes the muscles of the prostate and bladder neck, aiding in urination. Alfuzosin can be used in study of benign prostatic hyperplasia (BPH) ^[1] .

HY-B0391S1

Naftopidil-d5
Naftopidil-d₅ is deuterium labeled Naftopidil. Naftopidil (KT-611) is is a selective alpha1-adrenoceptor antagonist, with Kis of 3.7 nM, 20 nM and 1.2 nM for the cloned human α1a-, α1b- and α1d-adrenoceptor subtypes, respectively. Naftopidil has antiproliferative effects. Naftopidil can be used for the research of prostate hyperplasia[1][2].

HY-B0702S

Nicergoline-13C,d3
Nicergoline- ¹³C,d₃ is the ¹³C- and deuterium labeled Nicergoline. Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

α-1 adrenoceptor antagonist

Inhibitors & Agonists

Fluorescent Dye

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products